Loading...
ESMO congress Lung Cancer 20222025-01-28T17:10:22+01:00

ESMO 2022 Lung Cancer – hybrid, Paris

Lecture Board: Maximilian Hochmair, MD; Wenhua Liang, MD; Charles Swanton, FRS, FMedSci

Medical Writer: Judith Moser, MD

DOWNLOADS

All downloads from ESMO 2022 – lung cancer

ESMO 2022 Lung Cancer and Solid Tumor Slide Kit

Slide Kit NSCLC, gastric cancer and other solid tumors

ESMO 2022 Lung Cancer

Full report (english)

EXPERT VIDEOS

All video interviews from ESMO Lung Cancer 2022

Gérard Zalcman discusses recent findings regarding the duration of immune checkpoint inhibitor treatment in patients with NSCLC, expectations of checkpoint inhibitor therapy in the setting of unresectable malignant pleural mesothelioma and how the treatment of patients with malignant pleural mesothelioma might be further optimized based on molecular findings.

Marina Garassino comments on checkpoint inhibition in lung cancer patients with oncogenic drivers, highlights novel developing therapies in EGFR-mutant NSCLC patients with resistance to TKIs, summarizes the most relevant findings presented at ESMO 2022 in terms of the management of patients with previously untreated, metastatic non-squamous and squamous NSCLC without EGFR/ALK alterations as well as patients with extensive-stage small-cell lung cancer; and finally discusses how artificial intelligence can be used to predict the efficacy of immunotherapy in lung cancer patients.

Noemi Reguart outlines if EGFR-directed treatment in the setting of advanced NSCLC should be based on T790M monitoring in clinical practice, outlines recent insights gained in the negative CANOPY-A trail using the anti-IL-1β antibody canakinumab after resection of early-stage NSCLC and summarizes the current treatment landscape in Europe with respect to small-cell lung cancer.

Go to Top